Insider buying last 90 days
$1.25Min 2 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Jun 24 | Lauren M Tyler Director | Purchase | $149K |
| Jun 22 | Dermot Mark Durcan Director | Purchase | $1.10M |
From Form 4 filings, dated to when each was filed.
NYSE: COR
Cencora (COR) Stock Analysis & Forecast
$308.78−0.63 (−0.2%)
Close on Sep 18, 2026. Page updated Sep 19, 9:17 pm ET.
Gekko Brief
AI summaryCencora (COR) closes at $308.78, down 0.2%, and sits below both its 50-day average of $316.62 and 200-day average of $319.83, with the 50-day below the 200-day. The GekkoIndex reads 65.8, placing the stock in the Accumulation zone. Price stands 28.7% below Gekko Fair Value of $433.12.
The past week's coverage centers on Cencora's fiscal third-quarter results, with revenue up 5.1% and adjusted EPS up 12.0%, alongside raised full-year guidance and $1 billion in stock repurchases. Separate items note portfolio activity from institutional holders: Corient Private Wealth LP lifted its stake by 102.9% during the second quarter to 37,601 shares, while Bank of America Corp DE established a new position of 3,733,921 shares, both per 13F filings. Cencora also presented at two healthcare conferences during the period.
Looking ahead, Cencora's next earnings report is set for 4 November 2026, 45 days away and beyond a typical 20-trading-day holding window; the prior report on 5 August produced a 6.1% reaction, with EPS beating estimates in each of the last 8 quarters. Over the last 90 days, insiders made 2 open-market purchases totaling $1,245,387. Seasonality over the next 20 trading days has averaged a 3.7% gain across 5 years, positive in 4 of them. Analyst coverage from 12 firms shows 9 buy and 3 hold ratings, with a consensus target of $369.31.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $308.78200-day averageGekko Fair Value $433.12
Key stats
- Market cap
- $60.08B
- P/E ratio
- 23.6
- Forward P/E
- 16
- EPS, TTM
- $13.09
- Revenue, TTM
- $332.8B
- Profit margin
- 0.8%
- Dividend yield
- 0.74%
- Beta
- 0.57
- Volume
- 3.22M avg 1.20M
- 1-year return
- +6.8%
- Typical daily move
- ±2.3%
- Typical 20-day move
- ±4.6%
- 50-day average
- $316.62
- 200-day average
- $319.83
- Next earnings
- Nov 4 before open
- Shares outstanding
- 190.8M
Cencora swing-trade checklist
Cencora scores 5 supportive, 0 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
5 supportive0 mixed1 headwind
- Trendheadwind
Below 50 and 200-day
Close $308.78 is below the 50-day ($316.62) and 200-day ($319.83) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
65.8, Accumulation
Reading 65.8 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
28.7% below
Price is 28.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: 2 open-market insider purchases.
See smart money - Earnings risksupportive
Reports in 45 days
Next report Nov 4, 2026, 45 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+3.7% on average
From this point in the calendar, the next 20 trading days averaged +3.7% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Cencora stock chart and price history
Cencora closed at $308.78 on Sep 18, 2026, +6.8% over the past year, inside a 52-week range of $244.82 to $377.54.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −2.6%
- 3 months
- +13.6%
- 6 months
- −6.9%
- 1 year
- +6.8%
The full COR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open COR in Gekko
Follow Cencora through every session
Put COR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track COR in GekkoFree for 7 days. No credit card required.
About Cencora
Cencora sources and distributes pharmaceutical products across the United States and international markets. Through its U.S. Healthcare Solutions segment, it supplies generic and injectable medications, over-the-counter health items, and home healthcare equipment, along with specialized products such as plasma, blood derivatives, and vaccines. The company is also known for its work in animal health, offering pharmaceuticals, vaccines, parasiticides, diagnostics, and feed ingredients for companion and production animals.
Cencora's customers include acute care hospitals, health systems, retail and mail-order pharmacies, medical clinics, oncologists, dialysis clinics, and other healthcare providers. Beyond product supply, it provides pharmacy management, staffing, and consulting services, builds supply management software, handles packaging for institutional and retail healthcare settings, and supports clinical trials, post-market approval, and commercialization for biotechnology and pharmaceutical manufacturers, including data analytics and outcomes research. Its International Healthcare Solutions division handles global pharmaceutical wholesale operations, commercialization support, and logistics for the biopharmaceutical sector, reaching pharmacies, doctors, health centers, and hospitals abroad.
The company traces back to 1871 and was previously named AmerisourceBergen Corporation before taking the name Cencora in August 2023. It is headquartered in Conshohocken, Pennsylvania, and its shares are listed on the NYSE under the ticker COR.
- Listed
- NYSE
- Sector
- Distribution services
- Industry
- Medical distributors
- Website
- cencora.com
Cencora GekkoIndex: the smart money zone
Cencora’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 65.8, in the Accumulation zone, up 8 points over five sessions.
65.8Accumulation
Up 8 points over five sessions, from the Neutral zone.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 27 | −0.5% | +4.6% | ||
| Accumulation (current zone) | 169 | +0.6% | +2.0% | ||
| Neutral | 406 | +0.4% | +1.0% | ||
| Distribution | 58 | −0.4% | +0.2% | ||
| Selling | 2 | Too few readings yet | |||
Average COR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the COR price, zone by zone.Track COR in Gekko
Is Cencora stock overvalued? Gekko Fair Value
Cencora trades 28.7% below Gekko Fair Value of $433.12, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Cencora shares are worth, recalculated every trading day.
$433.12
Gekko Fair Value, Sep 19, 2026
28.7% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open COR in Gekko
Cencora insider and Congress trading
Insiders filed 2 open-market purchases in Cencora worth $1.25M, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in COR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for COR, plotted on the chart in Gekko.Open COR in Gekko
Buybacks
Cencora has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $1.00B
- As a share of market cap
- 1.66%
From company filings.
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold COR.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Cencora earnings: next date and track record
Cencora reports on Nov 4, 2026, before the open (45 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected before the open, 45 days away
- EPS estimate
- $4.57
- Revenue estimate
- $88.14B
8 of 8reports beat the EPS estimate
±5.6%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- Cencora reported solid fiscal Q3 2026 results driven by strong execution in U.S. Healthcare Solutions (notably specialty, MSOs RCA and OneOncology) and International growth. Consolidated revenue was $84.8 billion, up 5%; consolidated adjusted gross profit increased 23% and adjusted gross margin expanded to 4.16%. Adjusted operating income grew 17% and adjusted EPS rose 12% (helped by $1 billion opportunistic share repurchases). Management raised fiscal 2026 adjusted EPS guidance and highlighted continued investments in specialty, digital transformation, and talent. OneOncology outperformed expectations and is expected to be roughly EPS neutral on a 12-month basis net of financing; accounting treatment for a UUG noncontrolling interest was clarified with no operating income impact. Management emphasized the long-term opportunity across MSOs, clinical trials, and specialty logistics (World Courier / 3PL) while noting continued monitoring of policy/regulatory initiatives (340B, ASP/GLOBE demo).
- Guidance
- Raised fiscal 2026 adjusted EPS guidance to $17.75 - $17.95. Q4 guidance implies strong double-digit growth across reportable segments at the midpoint. OneOncology is expected to be neutral to adjusted EPS on a 12-month basis net of financing. Management will provide 2027 outlook on the November call.
- Risks flagged
- Policy and regulatory uncertainty (340B program changes, proposed ASP rule changes / GLOBE demonstration) that could affect reimbursement and physician economics; competitive dynamics in specialty logistics/3PL; customer-specific dynamics (losses or in-sourcing by large customers); timing effects and accounting items (held-for-sale accounting impacts); general market and utilization variability in specialty and oncology.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $4.48 est $4.37 | $84.75B est $84.31B | +6.1% |
| May 6, 2026 | $4.75 est $4.73 | $78.36B est $81.09B | −16.4% |
| Feb 4, 2026 | $4.08 est $4.05 | $85.93B est $86.06B | −2.7% |
| Nov 5, 2025 | $3.84 est $3.79 | $83.73B est $83.46B | +4.6% |
| Aug 6, 2025 | $4.00 est $3.85 | $80.66B est $80.09B | −4.8% |
| May 7, 2025 | $4.42 est $4.11 | $75.45B est $75.68B | −2.4% |
| Feb 5, 2025 | $3.73 est $3.52 | $81.49B est $78.31B | −2.2% |
| Nov 6, 2024 | $3.34 est $3.22 | $79.05B est $77.62B | +5.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Cencora stock forecast and analyst price targets
Analysts’ average 12-month price target for Cencora is $369.31, +19.6% from the last close, from 12 firms rating the stock in the last 90 days.
$369.31consensus 12-month target, +19.6% from the last close
Now $308.78Avg $369.31
Low $330High $430
Each firm’s latest rating in the last 90 days: 12 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 19 | RBC Capital | $330 | +6.9% |
| Aug 13 | Barclays | $350 | +13.3% |
| Aug 13 | Evercore ISI | $350 | +13.3% |
| Aug 12 | Bank of America Securities | $330 | +6.9% |
| Aug 11 | Wells Fargo | $395 | +27.9% |
+2.0%average 20-day move after past Accumulation readings
+3.7%average move over the next 20 trading days in the last 5 years
±2.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Cencora seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Cencora averaged +3.7% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.9% | 3 of 5 |
| Next 10 trading days | −0.4% | 2 of 5 |
| Next 15 trading days | +1.9% | 3 of 5 |
| Next 20 trading days | +3.7% | 4 of 5 |
| Next 30 trading days | +6.5% | 5 of 5 |
For scale, COR’s typical 20-trading-day move in either direction is about 4.6%.
Cencora market cap and key statistics
Cencora’s market cap is $60.08B, with a P/E ratio of 23.6 and revenue of $332.8B over the last twelve months.
Valuation
- Market cap
- $60.08B
- P/E ratio
- 23.6
- Forward P/E
- 16
- EPS, TTM
- $13.09
- Gekko Fair Value
- $433.12
Trading
- Volume
- 3.22M
- Avg volume, 20 days
- 1.20M
- 52-week high
- $377.54
- 52-week low
- $244.82
- Shares outstanding
- 190.8M
Financials
- Revenue, TTM
- $332.8B
- Profit margin
- 0.8%
- Return on equity
- 96.9%
- Quarterly earnings growth, YoY
- +11.9%
Risk and income
- Beta
- 0.57
- Typical daily move
- ±2.3%
- Typical 20-day move
- ±4.6%
- Dividend yield
- 0.74%
Cencora stock news this week
6 headlines about Cencora from the past week, newest first, each linking to the publisher.
- Cencora (COR) Raised Guidance and Bought Back $1B. What’s the Catch?Insider Monkey, Sep 19
- Here's Why Cencora (COR) is a Strong Value StockZacks Investment Research, Sep 18
- Corient Private Wealth LP Purchases 19,068 Shares of Cencora, Inc. $CORDefense World, Sep 17
- Cencora, Inc. (COR) Presents at 2026 Global Healthcare Conference TranscriptSeeking Alpha, Sep 15
- Cencora, Inc. (COR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha, Sep 15
- 3,733,921 Shares in Cencora, Inc. $COR Purchased by Bank of America Corp DEDefense World, Sep 15
Cencora peers
Cencora’s 3 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| MCKMcKesson | Accumulation | 14.1% below |
| CAHCardinal Health | Accumulation | 41.8% below |
| HSICHenry Schein | Buying | 0.1% above |
A peer links to its own page where one exists.
Cencora stock FAQ
What is Cencora’s market cap?
Cencora’s market cap is $60.08B at the Sep 18, 2026 close of $308.78, with 190.8M shares outstanding. The shares trade on a P/E ratio of 23.6.
What is the Cencora stock forecast?
The consensus analyst 12-month price target for Cencora is $369.31, +19.6% from the last close. Of the 12 firms that rated the stock in the last 90 days, 9 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Cencora stock overvalued or undervalued?
On Gekko’s estimate Cencora is undervalued: the Sep 18, 2026 close of $308.78 is 28.7% below Gekko Fair Value of $433.12. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Cencora report earnings next?
Cencora is expected to report on Nov 4, 2026, before the market opens (45 days away). Analysts expect earnings of $4.57 per share on revenue of $88.14B. Cencora beat the earnings estimate in 8 of its last 8 reports, moving 5.6% on average across the report.
What is Cencora’s 52-week high and low?
Cencora’s 52-week high is $377.54 and its 52-week low is $244.82; it closed at $308.78 on Sep 18, 2026, +6.8% over the past year.
Is Cencora stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (gekkoindex, fair value, smart money, earnings risk and seasonality) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Cencora the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.